Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.51−0.01 (-1.56%)
Close on Nov 18, 2026Market cap $14.02MP/E –Yield –
Citius Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Citius Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$61.38M. For fiscal 2025 it was -$38.53M. The highest annual figure on record is -$19.62K in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$38.53M | – |
| FY2024 | Sep 30, 2024 | -$42.00M | – |
| FY2023 | Sep 30, 2023 | -$36.73M | – |
| FY2022 | Sep 30, 2022 | -$33.32M | – |
| FY2021 | Sep 30, 2021 | -$23.53M | – |
| FY2020 | Sep 30, 2020 | -$17.71M | – |
| FY2019 | Sep 30, 2019 | -$15.60M | – |
| FY2018 | Sep 30, 2018 | -$13.79M | – |
| FY2017 | Sep 30, 2017 | -$9.99M | – |
| FY2016 | Sep 30, 2016 | -$7.45M | – |
| FY2012 | Sep 30, 2012 | -$19.62K | – |
| FY2011 | Sep 30, 2011 | -$25.64K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$11.73M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$32.19M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$9.02M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$8.44M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$8.79M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$11.26M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$10.04M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$11.05M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$10.63M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$10.97M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$9.34M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$10.12M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$7.25M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$7.55M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$8.92M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$7.59M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$9.26M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$5.20M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$5.98M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$4.19M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$8.16M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$4.14M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$4.69M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$4.43M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$4.45M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$3.66M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$4.43M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$3.64M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$3.87M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$3.66M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$2.02M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.87M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$3.24M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.40M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$2.26M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$2.54M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$2.78M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$3.41M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$2.13M | – |
See a number that looks wrong?